Vera Therapeutics (VERA) stock: insider trades, news & valuation
Net sellingShare price and insider trades
Vera Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $250K and 8 sold $12.3M of VERA stock on the open market.
Get emailed when insiders cluster-buy stocks like VERA
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
VERA insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $5.2M | 10 |
| Q2 2026 | — | 0 | $3.8M | 11 |
| Q1 2026 | — | 0 | $1.4M | 7 |
| Q4 2025 | $250K | 1 | $1.9M | 5 |
Valuation, profit and volume
Summary
Over the past 12 months, 1 Vera Therapeutics, Inc. insider reported open-market purchases totaling $250K, while 8 insiders reported sales totaling $12.3M. Among insiders with enough purchase history to measure, Patrick G Enright (Director) has the highest Insider Score at 98. 24 of 33 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 17SEC | Marshall FordyceCEO, President | Sell Plan | 18,500235,244 held (−7%) | $37.00 | $684K | -19.2% | — |
| Sep 4SEC | Marshall FordyceCEO, President | Sell Plan | 18,500235,244 held (−7%) | $35.12 | $650K | -14.9% | — |
| Aug 12SEC | Marshall FordyceCEO, President | Sell Plan | 32,550247,944 held (−12%) | $42.07 | $1.4M | -29.0% | — |
| Aug 12SEC | Marshall FordyceCEO, President | Sell Plan | 18,412235,332 held (−7%) | $37.93 | $698K | -21.2% | — |
| Aug 12SEC | Marshall FordyceCEO, President | Sell Plan | 14,219239,525 held (−6%) | $36.64 | $521K | -18.4% | — |
| Aug 12SEC | Marshall FordyceCEO, President | Sell Plan | 10,500237,444 held (−4%) | $42.86 | $450K | -30.3% | — |
| Aug 12SEC | Marshall FordyceCEO, President | Sell Plan | 4,281235,244 held (−2%) | $37.09 | $159K | -19.4% | — |
| Aug 12SEC | Marshall FordyceCEO, President | Sell Plan | 2,200235,244 held (−1%) | $43.59 | $96K | -31.5% | — |
| Aug 12SEC | Marshall FordyceCEO, President | Sell Plan | 1,000280,494 held (−0%) | $40.78 | $41K | -26.7% | — |
| Aug 12SEC | Marshall FordyceCEO, President | Sell Plan | 88235,244 held (−0%) | $38.43 | $3K | -22.2% | — |
| Jul 9SEC | Marshall FordyceCEO, President | Sell Plan | 32,550164,694 held (−17%) | $42.07 | $1.4M | -29.0% | — |
| Jul 9SEC | Marshall FordyceCEO, President | Sell Plan | 10,500154,194 held (−6%) | $42.86 | $450K | -30.3% | — |
| Jul 9SEC | Marshall FordyceCEO, President | Sell Plan | 2,200151,994 held (−1%) | $43.59 | $96K | -31.5% | — |
| Jul 9SEC | Marshall FordyceCEO, President | Sell Plan | 1,000197,244 held (−1%) | $40.78 | $41K | -26.7% | — |
| Jun 24SEC | Marshall FordyceCEO, President | Sell Plan | 18,412198,332 held (−8%) | $37.93 | $698K | -21.2% | — |
| Jun 24SEC | Marshall FordyceCEO, President | Sell Plan | 88198,244 held (−0%) | $38.43 | $3K | -22.2% | — |
| May 13SEC | Marshall FordyceCEO, President | Sell Plan | 14,219221,025 held (−6%) | $36.64 | $521K | -18.4% | — |
| May 13SEC | Marshall FordyceCEO, President | Sell Plan | 4,281216,744 held (−2%) | $37.09 | $159K | -19.4% | — |
| Apr 15SEC | Marshall FordyceCEO, President | Sell Plan | 14,130244,065 held (−5%) | $43.66 | $617K | -31.6% | — |
| Apr 15SEC | Marshall FordyceCEO, President | Sell Plan | 7,921236,144 held (−3%) | $44.58 | $353K | -33.0% | — |
| Apr 15SEC | Marshall FordyceCEO, President | Sell Plan | 900235,244 held (−0%) | $45.51 | $41K | -34.3% | — |
| Feb 25SEC | Marshall FordyceCEO, President | Sell | 16,925257,163 held (−6%) | $41.98 | $711K | -28.8% | — |
| Feb 25SEC | Sean GrantCFO | Sell | 4,949114,181 held (−4%) | $41.98 | $208K | -28.8% | — |
| Feb 25SEC | Joseph R YoungSvp, Finance, Chief Acct Offcr | Sell | 3,11764,722 held (−5%) | $41.98 | $131K | -28.8% | — |
| Feb 25SEC | David Lee JohnsonCOO | Sell | 2,57945,727 held (−5%) | $41.98 | $108K | -28.8% | — |
| Feb 25SEC | William D. TurnerChief Regulatory Officer | Sell | 2,18745,313 held (−5%) | $41.98 | $92K | -28.8% | — |
| Feb 25SEC | Robert BrennerChief Medical Officer | Sell | 2,15150,947 held (−4%) | $41.98 | $90K | -28.8% | — |
| Feb 25SEC | Laurence Matthew SkeltonChief Commercial Officer | Sell | 1,58264,218 held (−2%) | $41.98 | $66K | -28.8% | — |
| Dec 17SEC | William D. TurnerChief Regulatory Officer | Sell Plan | 10,00022,500 held (−31%) | $50.08 | $501K | -40.3% | — |
| Dec 15SEC | Patrick G EnrightDirector | Buy | 5,882new position | $42.50 | $250K | -29.7% | 98 |
| Dec 10SEC | William D. TurnerChief Regulatory Officer | Sell Plan | 10,00022,500 held (−31%) | $45.31 | $453K | -34.1% | — |
| Dec 4SEC | William D. TurnerChief Regulatory Officer | Sell Plan | 10,00022,500 held (−31%) | $40.00 | $400K | -25.3% | — |
| Nov 25SEC | Jason S CarterGeneral Counsel | Sell | 3,86449,136 held (−7%) | $27.82 | $107K | +7.4% | — |
| Nov 13SEC | Joseph R YoungSvp, Finance, Chief Acct Offcr | Sell | 15,00047,839 held (−24%) | $29.06 | $436K | +2.8% | — |
Insiders at Vera Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Marshall FordyceCEO, President | — | $9.7M | Sep 17, 2026 | — |
| William D. TurnerChief Regulatory Officer | — | $1.4M | Feb 25, 2026 | — |
| Patrick G EnrightDirector | $250K | — | Dec 15, 2025 | 98 |
| Joseph R YoungSvp, Finance, Chief Acct Offcr | — | $567K | Feb 25, 2026 | — |
| Sean GrantCFO | — | $208K | Feb 25, 2026 | — |
| David Lee JohnsonCOO | — | $108K | Feb 25, 2026 | — |
| Jason S CarterGeneral Counsel | — | $107K | Nov 25, 2025 | — |
| Robert BrennerChief Medical Officer | — | $90K | Feb 25, 2026 | — |
| Laurence Matthew SkeltonChief Commercial Officer | — | $66K | Feb 25, 2026 | — |
VERA stock: common questions
Are Vera Therapeutics, Inc. insiders buying VERA stock?
In the past 12 months, 1 insiders reported open-market purchases of VERA worth $250K. The latest was Director Patrick G Enright bought $250K of VERA at $42.50 — first open-market purchase in our records; opens a new position.
Are Vera Therapeutics, Inc. insiders selling VERA stock?
8 insiders reported sales worth $12.3M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is VERA's 52-week range?
Over the past year VERA has traded between $24.10 and $55.67. It last closed at $29.88 on Oct 9, 2026.